Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Silver ETF (AGQ) vs AstraZeneca plc (AZN) Price & Performance

ProShares Ultra Silver ETFTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Silver ETF vs AstraZeneca plc — how do they compare? ProShares Ultra Silver ETF trades at $81.45, while AstraZeneca plc trades at $158.62 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while ProShares Ultra Silver ETF pays none. Which is the better fit depends on your goals.

AGQAZN
Sector
Leveraged / InverseHealth
52-Week High
$400.47$209.48
52-Week Low
$49.73$147.06
Market Cap
$248.14B
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Silver ETF

AGQ, a leveraged silver ETF, trades at $81.11, down 0.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights volatility, with articles noting a 9.39% surge on silver rallies but structural decay risks from daily-reset leverage. Financial ratios are unavailable as AGQ is an ETF tracking silver futures, not a company with fundamentals.

The outlook hinges on silver price momentum, offering amplified gains but high risk from leverage decay and silver volatility. Key risks include underperformance versus unlevered ETFs and sharp declines during silver sell-offs, as seen in a 16% drop in June 2026. Investors should weigh silver's bullish trend against ETF-specific drawbacks.

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Silver ETF

AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.

Read more on AGQ

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN